Core Viewpoint - The company, Stone Four Pharmaceutical Group, has received production registration approvals from the National Medical Products Administration for seven pharmaceutical products, indicating a significant advancement in its product portfolio and market positioning [1]. Group 1: Product Approvals - The company has obtained approval for Arginine Perindopril Tablets (10mg), classified as a Class 4 chemical drug, making it the second domestic company to receive this approval. This product is primarily used for treating hypertension and congestive heart failure [1]. - The company has also received approval for Progesterone Injection (II) (1.112ml: 25mg), classified as a Class 3 chemical drug, which is used for progesterone supplementation in assisted reproductive technology (ART) [1]. - Approval has been granted for Labetalol Hydrochloride Injection (20ml: 100mg), also a Class 3 chemical drug, used for various types of hypertension, especially hypertensive crises, and for blood pressure control before surgery [1]. - Calcium Chloride Injection (10ml: 1g), classified as a Class 3 chemical drug, is approved for treating acute hypocalcemia and magnesium poisoning [1]. - The company has received approval for Compound Electrolyte Acetate Sodium Injection (500ml), a Class 3 chemical drug, used for treating isotonic dehydration with mild acidosis [1]. - Approval has been granted for Compound Electrolyte Injection (V) (500ml), classified as a Class 3 chemical drug, which serves as a source of water and electrolytes for adults [1]. - The company has also received approval for Levosalbutamol Hydrochloride Nebulization Solution (3ml: 0.63mg), a Class 3 chemical drug, used for treating or preventing bronchospasm in adults and children over six years old with reversible airway obstructive diseases [1].

Core Viewpoint - The company, Shijiazhuang Pharmaceutical Group, has received production registration approvals from the National Medical Products Administration for seven pharmaceutical products, indicating a significant advancement in its product portfolio and market positioning [1]. Group 1: Product Approvals - The company has obtained approvals for the following seven drugs: 1. Arginine Perindopril Tablets (10mg), classified as a Class 4 chemical drug, is the second domestic company to receive approval, primarily used for treating hypertension and congestive heart failure [1]. 2. Progesterone Injection (II) (1.112ml: 25mg), classified as a Class 3 chemical drug, is used for progesterone supplementation in assisted reproductive technology (ART) [1]. 3. Labetalol Hydrochloride Injection (20ml: 100mg), classified as a Class 3 chemical drug, is indicated for various types of hypertension, especially hypertensive crises, and for blood pressure control before surgery [1]. 4. Calcium Chloride Injection (10ml: 1g), classified as a Class 3 chemical drug, is primarily used for treating acute hypocalcemia and magnesium poisoning [1]. 5. Compound Electrolyte Acetate Injection (500ml), classified as a Class 3 chemical drug, is used for treating isotonic dehydration with mild acidosis and for replenishing extracellular fluid and blood volume loss [1]. 6. Compound Electrolyte Injection (V) (500ml), classified as a Class 3 chemical drug, serves as a source of water and electrolytes for adults [1]. 7. Levosalbutamol Nebulization Solution (3ml: 0.63mg), classified as a Class 3 chemical drug, is used for treating or preventing bronchospasm in adults and children over 6 years old with reversible airway obstructive diseases [1].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 承董事局命 執行董事兼公司秘書 周興揚 香港，二零二五年九月五日 於本公告日期，董事局成員包括執行董事曲繼廣先生、蘇學軍先生、孟國先生、周興揚先生及 曲婉蓉女士，非執行董事劉文軍先生，以及獨立非執行董事王亦兵先生、周國偉先生及姜廣策 先生。 (6) 複方電解質注射液(V) (500ml)，屬於化學藥品第3類，視同通過一致性評價。複方電解質注 射液主要用於成人作為水、電解質的補充源和鹼化劑;及 (7) 鹽酸左沙丁胺醇霧化吸入溶液(3ml: 0.63mg)，屬於化學藥品第3類，視同通過一致性評價。 鹽酸左沙丁胺醇霧化吸入溶液主要用於治療或預防成人及6歲以上兒童可逆性氣道阻塞性 疾病引起的支氣管痙攣。誠如本公司日期為二零二三年九月四日之公告所載，本集團的鹽 酸左沙丁胺醇原料藥已獲國家藥監局批准登記成為在上市製劑使用的原料藥。 自願公告 產品開發的最新進展 石四藥集團有限公司（「本公司」，連同其附屬公司，「本 ...

Group 1 - The core point of the article is that 石四药集团 (Shijiazhuang Pharmaceutical Group) has seen a significant stock price increase of nearly 14% following the announcement of obtaining production registration approvals for two pharmaceutical products from the National Medical Products Administration of China [1] - The company has received production registration approvals for 乌拉地尔缓释胶囊 (Urapidil Sustained-release Capsules, 30mg) and 盐酸尼卡地平氯化钠注射液 (Nicardipine Hydrochloride Sodium Injection, 200ml), both classified as Category 3 chemical drugs, marking them as the first domestic company to receive such approvals [1] - Additionally, the company has obtained production registration approval for 盐酸屈他维林注射液 (Sufentanil Hydrochloride Injection, 2ml), classified as a Category 4 chemical drug, also indicating successful consistency evaluation [1] Group 2 - Citigroup's research report indicates that in the 11th round of drug procurement, 石四药集团 has 11 drugs, including Bromhexine, which is expected to account for approximately 1.5% of projected sales in 2024 [1] - The report suggests that the company has a strong chance of winning contracts for peritoneal dialysis solutions and renewing contracts for other products [1] - Citigroup views 石四药集团 as a winner among generic drug companies and the largest beneficiary of drug procurement policies [1]

Group 1 - The core viewpoint of the report indicates that CSPC Pharmaceutical Group's revenue for the first half of the year decreased by 35% year-on-year to HKD 2.147 billion, primarily due to a decline in sales volume of intravenous (IV) infusions and ampoule injections [1] - Net profit fell by 59% to HKD 284 million, reflecting the challenging market conditions [1] - In the 11th round of drug centralized procurement (GPO), CSPC has 11 drugs, including bromhexine, which are expected to account for approximately 1.5% of sales in 2024, with a significant opportunity to win peritoneal dialysis fluid contracts and renew other products [1] Group 2 - Citigroup has revised its revenue forecasts for CSPC for the fiscal years 2025 to 2027 down by 21%, 20%, and 21% respectively, and lowered earnings per share forecasts by 38% to reflect the latest sales trends and lower gross margins due to price declines [1] - The target price for CSPC has been reduced from HKD 7 to HKD 5, while maintaining a "buy" rating, as the company is viewed as a winner among generic drug firms and the largest beneficiary of drug GPOs [1]

Group 1 - The latest shareholder equity disclosure for Stone Four Pharmaceutical Group (02005) and Huaxin Cement (06655) was conducted on September 5, 2025 [1] - China Pharmaceutical Company Limited increased its holdings in Stone Four Pharmaceutical Group from 878 million shares to 879 million shares, representing a holding percentage change from 29.74% to 29.77% [2] - Qu Jiguang increased his holdings in Stone Four Pharmaceutical Group from 1.169 billion shares to 1.170 billion shares, with a holding percentage change from 39.61% to 39.64% [2] Group 2 - Liu Weisheng acquired 20,000 shares in Huaxin Cement, changing his holding from 0 shares to 20,000 shares, resulting in a holding percentage of 0% [2]

Group 1 - The core point of the article is that Qu Jiguang, the Executive Director, Chairman, and CEO of China Pharmaceutical Group (stock code: 02005.HK), increased his shareholding by purchasing 880,000 shares at an average price of HKD 2.9652 per share, totaling approximately HKD 2.6094 million [1][2] - Following this transaction, Qu Jiguang's total shareholding increased to 1,169,862,000 shares, raising his ownership percentage from 39.61% to 39.64% [1][2]

Group 1 - The company, Shijiazhuang Fourth Pharmaceutical Group, announced on September 1 that it has obtained the drug production registration certificate from the National Medical Products Administration for Allopurinol Tablets (0.1g), classified as a Class 3 chemical drug, which is considered to have passed the consistency evaluation [2] - Allopurinol Tablets are primarily used for the treatment of primary or secondary gout patients, patients undergoing treatment for leukemia, lymphoma, and malignant tumors, as well as for the treatment of recurrent calcium oxalate stone patients [2]

Core Viewpoint - The company, Stone Four Pharmaceutical Group, has obtained the drug production registration approval from the National Medical Products Administration of China for Allopurinol Tablets (0.1g), classified as a Class 3 chemical drug, which is considered equivalent to passing the consistency evaluation [1] Group 1 - Allopurinol Tablets are primarily used for the treatment of patients with primary or secondary gout, leukemia, lymphoma, and malignant tumors, as well as for patients with recurrent calcium oxalate stones [1]

Core Viewpoint - The company has obtained the drug production registration approval for Allopurinol Tablets (0.1g) from the National Medical Products Administration of China, which is classified as a Class 3 chemical drug and is considered to have passed the consistency evaluation [1] Group 1 - Allopurinol Tablets are primarily used for the treatment of patients with primary or secondary gout, leukemia, lymphoma, and malignant tumors, as well as for patients with recurrent calcium oxalate stones [1]